DV1 (TFA)

DV1 TFA is a selective antagonist for CXC chemokine receptor 4 (CXCR4) . DV1 TFA exhibits antiviral activity by blocking HIV-1 entry through the CXCR4 co-receptor[1].

12352209

CXCR; HIV

Anti-infection; GPCR/G Protein; Immunology/Inflammation

COVID-19-anti-virus

Infection

98.53

DMSO : 100 mg/mL (ultrasonic)

O=C([C@H](N)CC(C)C)NCC(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N1[C@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(NCC(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N2[C@H](C(N[C@@H](C(N3[C@@H](C(N)=O)CCC3)=O)CC(C)C)=O)CCC2)=O)CCCNC(N)=N)=O)CCCCN)=O)CCC(N)=O)=O)CC4=CC=C(O)C=C4)=O)=O)CC(C)C)=O)CS)=O)CS)=O)CCCCN)=O)CC(O)=O)=O)CCC1)=O)CCCNC(N)=N)=O)CC5=CNC=N5)=O)CC6=CNC7=CC=CC=C67)=O)CO)=O)C)=O.OC(C(F)(F)F)=O.[x]

C108H170N34O26S2.xC2HF3O2

2424.85 (free base)

[1]Zhu Y, et al., LC-MS/MS assay for the determination of a novel D-peptide antagonist of CXCR4 in rat plasma and its application to a preclinical pharmacokinetic study. J Pharm Biomed Anal. 2018 Nov 30;161:159-167.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P10427A/DV1-TFA-SDS-MedChemExpress.pdf

Peptides

No Development Reported